Purpose: Thymosin α 1 (Tα1) is an immunomodulatory polypeptide that enhances effector T-cell responses. In this large randomized study, we evaluated the efficacy and safety of combining Tα1 with dacarbazine (DTIC) and interferon alfa (IFN-α) in patients with metastatic melanoma. Patients and Methods: Four hundred eighty-eight patients were randomly assigned to five treatment groups: DTIC+IFN-α+Tα1 (1.6 mg); DTIC+IFN-α+Tα1 (3.2 mg); DTIC+IFN-α+Tα1 (6.4 mg); DTIC+Tα1 (3.2 mg); DTIC+IFN-α (control group). The primary end point was best overall response at study end (12 months). Secondary end points included duration of response, overall survival (OS), and progression-free survival (PFS). Patients were observed for up to 24 months. Results: Ten and 12 tumor responses were observed in the DTIC+IFN-α+Tα1 (3.2 mg) and DTIC+Tα1 (3.2 mg) groups, respectively, versus four in the control group, which was sufficient to reject the null hypothesis that P0 ≤ .05 (expected response rate of standard therapy) in these two arms. Duration of response ranged from 1.9 to 23.2 months in patients given Tα1 and from 4.4 to 8.4 months in the control group. Median OS was 9.4 months in patients given Tα1 versus 6.6 months in the control group (hazard ratio = 0.80; 95% CI, 0.63 to 1.02; P = .08). An increase in PFS was observed in patients given Tα1 versus the control group (hazard ratio = 0.80; 95% CI, 0.63 to 1.01; P = .06). Addition of Tα1 to DTIC and IFN-α did not lead to any additional toxicity. Conclusion: These results suggest Tα1 has activity in patients with metastatic melanoma and provide rationale for further clinical evaluation of this agent.

Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma / Maio, M.; Mackiewicz, A.; Testori, A.; Trefzer, U.; Ferraresi, V.; Jassem, J.; Garbe, C.; Lesimple, T.; Guillot, B.; Gascon, P.; Gilde, K.; Camerini, Roberta; Cognetti, F.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 28:10(2010), pp. 1780-1787. [10.1200/JCO.2009.25.5208]

Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma

CAMERINI, ROBERTA;Cognetti F.
2010

Abstract

Purpose: Thymosin α 1 (Tα1) is an immunomodulatory polypeptide that enhances effector T-cell responses. In this large randomized study, we evaluated the efficacy and safety of combining Tα1 with dacarbazine (DTIC) and interferon alfa (IFN-α) in patients with metastatic melanoma. Patients and Methods: Four hundred eighty-eight patients were randomly assigned to five treatment groups: DTIC+IFN-α+Tα1 (1.6 mg); DTIC+IFN-α+Tα1 (3.2 mg); DTIC+IFN-α+Tα1 (6.4 mg); DTIC+Tα1 (3.2 mg); DTIC+IFN-α (control group). The primary end point was best overall response at study end (12 months). Secondary end points included duration of response, overall survival (OS), and progression-free survival (PFS). Patients were observed for up to 24 months. Results: Ten and 12 tumor responses were observed in the DTIC+IFN-α+Tα1 (3.2 mg) and DTIC+Tα1 (3.2 mg) groups, respectively, versus four in the control group, which was sufficient to reject the null hypothesis that P0 ≤ .05 (expected response rate of standard therapy) in these two arms. Duration of response ranged from 1.9 to 23.2 months in patients given Tα1 and from 4.4 to 8.4 months in the control group. Median OS was 9.4 months in patients given Tα1 versus 6.6 months in the control group (hazard ratio = 0.80; 95% CI, 0.63 to 1.02; P = .08). An increase in PFS was observed in patients given Tα1 versus the control group (hazard ratio = 0.80; 95% CI, 0.63 to 1.01; P = .06). Addition of Tα1 to DTIC and IFN-α did not lead to any additional toxicity. Conclusion: These results suggest Tα1 has activity in patients with metastatic melanoma and provide rationale for further clinical evaluation of this agent.
2010
adolescent; adult; aged; antineoplastic combined chemotherapy protocols; dacarbazine; female; humans; interferon-alpha; male; melanoma; middle aged; thymalfasin; thymosin
01 Pubblicazione su rivista::01a Articolo in rivista
Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma / Maio, M.; Mackiewicz, A.; Testori, A.; Trefzer, U.; Ferraresi, V.; Jassem, J.; Garbe, C.; Lesimple, T.; Guillot, B.; Gascon, P.; Gilde, K.; Camerini, Roberta; Cognetti, F.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 28:10(2010), pp. 1780-1787. [10.1200/JCO.2009.25.5208]
File allegati a questo prodotto
File Dimensione Formato  
Maio_Large-randomized_2010.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 157.18 kB
Formato Adobe PDF
157.18 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1310607
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 57
social impact